Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 43,979	$ 36,516
Kyprolis
Disaggregation of Revenue [Line Items]
Total revenues	17,154	13,432
Kyprolis
Disaggregation of Revenue [Line Items]
Total revenues	6,228	4,622
Evomela
Disaggregation of Revenue [Line Items]
Total revenues	2,550	2,701
Teriparatide injection
Disaggregation of Revenue [Line Items]
Total revenues	3,500	2,911
Rylaze
Disaggregation of Revenue [Line Items]
Total revenues	2,609	1,649
Other
Disaggregation of Revenue [Line Items]
Total revenues	2,267	1,549
Captisol
Disaggregation of Revenue [Line Items]
Total revenues	10,622	12,122
Captisol - Core
Disaggregation of Revenue [Line Items]
Total revenues	10,622	6,226
Captisol - COVID
Disaggregation of Revenue [Line Items]
Total revenues	0	5,896
Contract revenue
Disaggregation of Revenue [Line Items]
Total revenues	16,203	10,962
License Fees
Disaggregation of Revenue [Line Items]
Total revenues	114	2,081
Milestone
Disaggregation of Revenue [Line Items]
Total revenues	15,300	5,993
Other
Disaggregation of Revenue [Line Items]
Total revenues	$ 789	$ 2,888